Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Clinical Protocols × Thoracic × Clear all

Phase

Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pneumonia 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1

Interventions

Cisplatin 15 Pemetrexed 13 Erlotinib Hydrochloride 13 Carboplatin 12 icotinib 8 Propofol 6 Gefitinib 6 Docetaxel 6 endostar protein 5 Saline Solution 5 Endostatins 5 lorlatinib 4 anlotinib 4 Nivolumab 4 Gemcitabine 4 Drug Therapy 4 Afatinib 4 tislelizumab 3 pembrolizumab 3 durvalumab 3 Zoledronic Acid 3 Vinorelbine 3 Sevoflurane 3 Radiotherapy 3 Paclitaxel 3 Dexamethasone 3 Acetaminophen 3 trilaciclib 2 pegfilgrastim 2 osimertinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04036721 2023-02-23

PROS-CONS

National Institute for Tuberculosis and Lung Diseases, Poland

Phase 4 Suspended

Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡